Spotlight on Seniors with Narcolepsy: Comorbidities and Management. [PDF]
Jiang RY, Duka S, Vendrame M.
europepmc +1 more source
A Comprehensive Review of Novel FDA-Approved Psychiatric Medications (2018-2022). [PDF]
Giliberto S +7 more
europepmc +1 more source
The translational potential of sleep and circadian rhythm disturbances as a biomarker of Alzheimer's disease [PDF]
Feldman, HH +8 more
core +1 more source
An updated systematic review and meta-analysis of modafinil for excessive daytime sleepiness in narcolepsy. [PDF]
Mann GS +5 more
europepmc +1 more source
Sodium Oxybate: Practical Considerations and Patient Perspectives. [PDF]
Lavender M, Martin C, Anderson D.
europepmc +1 more source
Healthcare Burden and Productivity Loss Due to Narcolepsy in Sweden. [PDF]
Giertz A +5 more
europepmc +1 more source
Aroxybutynin and atomoxetine (AD109) for the treatment of obstructive sleep apnea: Rationale, design and baseline characteristics of the phase 3 clinical trials. [PDF]
Taranto-Montemurro L +7 more
europepmc +1 more source
Related searches:
Solriamfetol for the Management of Excessive Daytime Sleepiness
Journal of Pharmacy Practice, 2021Objective: To review efficacy, safety, and place in therapy of solriamfetol for management of excessive daytime sleepiness (EDS) in patients with narcolepsy and obstructive sleep apnea (OSA). Methods: PubMed (1966 to January 2021) was searched using the terms solriamfetol, JZP-110, ADX-N05 and Sunosi.
Megan C Cuomo +2 more
openaire +2 more sources

